Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02242825

Enrollment

8148

Registered

2014-09-17

Start date

2006-01-31

Completion date

Unknown

Last updated

2014-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, blood glucose and HbA1c) in patients with essential hypertension and diabetes mellitus

Interventions

DRUGMicardis®

DRUGMicardisPlus®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Hypertension * Diabetes mellitus

Exclusion criteria

* Age \< 18 years

Design outcomes

Primary

Measure	Time frame
Change from Baseline in systolic blood pressure (SBP)	Baseline, after 6 months
Change from Baseline in diastolic blood pressure (DBP)	Baseline, afterr 6 months

Secondary

Measure	Time frame	Description
Assessment of efficacy by investigator on a 6-point scale	after 6 months	—
Change from Baseline in laboratory parameters	Baseline, after 6 months	Metabolic parameters - Triglyceride, total cholesterol, blood glucose and HbA1c
Assessment of tolerability by investigator on a 5-point scale	after 6 months	—
Assessment of metabolic effect on a 4-point scale	after 6 months	—
Number of patients with adverse events	up to 6 months	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026